Germany Goes to Beijing: What the Merz-Xi summit means for pharma and life sciences

A trade reset, an Airbus deal, and a Danaher subsidiary at the table — the real story is what didn’t get signed

On February 25-26, German Chancellor Friedrich Merz landed in Beijing for his first official China visit since taking office — and brought half of German industry with him. The delegation included roughly 30 senior executives from Volkswagen, Mercedes-Benz, Siemens, BMW, Bayer, and Adidas. Among them: Dr. Annette Rinck, CEO of Leica Microsystems, a Danaher company — one of the few life sciences representatives in a room otherwise dominated by automotive and industrial giants.

The symbolism matters.

What actually happened

The headline outcome was modest by diplomatic standards. The five documents signed covered climate change and green transition, cooperation in animal disease prevention, a poultry products protocol, and sports collaboration agreements for football and table tennis. As Reuters noted, the agreements were “narrowly targeted and in industries peripheral to both economies.”

The bigger deliverable came verbally. Merz told reporters that China had agreed to buy “up to 120” Airbus aircraft, adding that it “demonstrates how worthwhile such trips can be.” For investors, that’s the headline — but it’s an aerospace story, not a pharma one.

What is a pharma story is what Premier Li Qiang said at the table. Li told Merz that China wished to cooperate in areas including automobiles and chemicals, as well as emerging fields including artificial intelligence and biomedicine, and said China would “actively address the reasonable demands of foreign-invested enterprises from Germany.” Biomedicine mentioned explicitly, at head-of-government level, is not throwaway language.

The trade deficit problem — and why it hits life sciences

The uncomfortable backdrop to the entire visit was Germany’s widening trade imbalance with China. Merz told reporters that Chinese exporters had built massive trade surpluses with Germany, amounting to €90 billion last year — a deficit that had increased fourfold since 2020. “This dynamic is not healthy,” he said.

As The Diplomat noted, the visit should not be viewed as a strategic pivot, but as a focused attempt to rebalance an increasingly uneven economic relationship. For life sciences companies, that rebalancing has very specific implications: rare earth dependency, regulatory access, and the question of whether Chinese volume-based procurement policies — which have already cost Danaher significantly — will ease or intensify.

Where Leica fits — and what it signals for Danaher

According to the Leica Microsystems press release, Dr. Rinck used her remarks at the high-level economic roundtable — attended by both Premier Li and Chancellor Merz — to stress “reliable framework conditions, consistent industry standards, and open dialogue.” That’s corporate-speak for: we need regulatory predictability and we’re willing to show up at the highest level to get it.

Together with over 60 Chinese and German business leaders, Li and Merz attended the symposium of the China-Germany Economic Advisory Committee. Having a life sciences instruments CEO in that room, as reported in the Leica press release, is a deliberate positioning move — not a coincidence of scheduling.

For Danaher investors, this matters for a reason that goes beyond optics. The company has faced real headwinds in China from volume-based procurement reforms. A CEO-level presence at a bilateral government summit, at a moment when Beijing is publicly signaling openness to German life sciences cooperation, is exactly the kind of relationship capital that takes years to build and pays off in market access and regulatory predictability.

The bigger picture: Europe is choosing pragmatism over alignment

Merz is the latest in a string of Western leaders to visit Beijing in recent months, including UK Prime Minister Keir Starmer, French President Emmanuel Macron, and Canadian PM Mark Carney, amid the fallout from the Trump administration’s tariffs on long-established trade partners.

In his meeting with Merz, Xi Jinping called for stronger strategic dialogue and greater mutual trust, underscoring that stable China-Germany relations are essential to both European and global stability. Whether that framing holds when Merz flies to Washington the following week — where Trump’s trade posture points in exactly the opposite direction — is the real geopolitical cliffhanger.

For pharma and life sciences companies watching from the sidelines: the Germany-China relationship is being actively renegotiated, biomedicine is on the agenda, and the companies with government-level relationships are already in the room. You can read about the war in other news.